Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab versus platinum-doublet chemotherapy as first-line treatment for dMMR advanced or recurrent endometrial cancer
MOH_2022-03-08_010567Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab, carboplatin and paclitaxel in endometrial cancer (EC) and endometrial carcinosarcoma (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on MOH_2022-03-08_010567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-08_010567.